Sector News

Sanofi sponsors Parkinson’s Foundation’s genetic study with $1M for free testing

November 22, 2020
Life sciences

It’s estimated that 10% to 15% of people with Parkinson’s have a genetic form of the disease and Sanofi Genzyme is backing a new study to help find those people.

Working with the Parkinson’s Foundation, the effort, called PD GENEration, will provide free genetic testing, either by in-person blood testing at selected sites or by a telemedicine appointment combined with at-home cheek swabs. Follow-up counseling will also be provided to discuss the results. Sanofi will contribute $1 million to the study over the next two years.

The goal of the testing is to identify the specific genetic status of people with Parkinson’s, which can lead to better identification for clinical trials and more personalized therapies.

The Sanofi-backed study will inform participants when “trials become available that are relevant to their genetic status,” James Beck, senior VP and chief scientific officer at the Parkinson’s Foundation, said in an email.

“Because we are banking the DNA to share in a de-identified fashion, we are hopeful that the results obtained through this study will also impact future research to develop improved treatments and personalized medicine for Parkinson’s,” he said.

Today, there are limited genetic testing options for people with Parkinson’s. The tests are often expensive and not covered by insurance, and they use a chip technology that may only identify a few point mutations on the genes linked to Parkinson’s. The main issue, however, is that there is no genetic counseling, Beck said.

The response so far has been positive, with more than 500 people taking part and waiting lists already forming at the foundation’s existing sites, Beck said. The partners plan to add more testing sites at Parkinson’s Foundation Centers of Excellence across the country.

Beck sees the collaboration between Sanofi and the Parkinson’s Foundation as a natural fit.

“Sanofi is a leading pharma company that shares our vision of improving the lives of those affected by PD,” he said, adding that “it made perfect sense to join forces in this project.”

by Sharon Klahr Coey

Source: fiercepharma.com

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).